isease exacerbations account for the majority of asthma-related costs. Among children living in the United States, . 4 million asthma exacerbations occur each year, resulting in approximately 700,000 ED visits, 205,000 hospital admissions, and 200 deaths per year. 1,2 Without including prescriptions, costs related to pediatric asthma exacerbations accounted for $9.8 billion (63.2%) of the estimated $15.5 billion total asthma costs in the United States in 2002. 3 According to guidelines for the diagnosis and management of asthma from the National Heart, Lung and Blood Institute (NHLBI), two or more exacerbations requiring oral steroids per year place children in the persistent category, represent suboptimal control, and increase morbidity and mortality. 4 The prevalence of pediatric asthma exacerbations varies widely by ethnicity. Among Hispanic children living in the United States, the prevalence ranges from 2.9% in Mexicans to 11.8% in Puerto Ricans, and the rate of ED visits is 14.1% for Hispanics vs 10.8% for non-Hispanic whites. 2 The prevalence of childhood asthma in Costa Rica, a Hispanic American country, is among the highest in the world. 5 During phase 3 of the International Study for Asthma and Allergies in Childhood (ISAAC) study, the reported current prevalence of asthma was 34.8% for 6-to 7-year-olds and 25.5% for 13-to 14-year-olds; with 9.7% and 6.7%, respectively, reporting more than four exacerbations a year. Little is known, however, about risk factors for asthma Background: Asthma is a major public health problem that affects millions of children worldwide, and exacerbations account for most of its morbidity and costs. Primary-care providers lack efficient tools to identify children at high risk for exacerbations. We aimed to construct a clinical score to help providers to identify such children. Methods: Our main outcome was severe asthma exacerbation, which was defi ned as any hospitalization, urgent visit, or systemic steroid course for asthma in the previous year, in children. A clinical score, consisting of a checklist questionnaire made up of 17 yes-no questions regarding asthma symptoms, use of medications and health-care services, and history, was built and validated in a cross-sectional study of Costa Rican children with asthma. It was then evaluated using data from the Childhood Asthma Management Program (CAMP), a longitudinal trial cohort of North American children. Results: Compared with children at average risk for an exacerbation in the Costa Rican validation set, the odds of an exacerbation among children in the low-risk (OR, 0.2; 95% CI, 0.1-0.4) and high-risk (OR, 5.4; 95% CI, 1.5-19.2) score categories were signifi cantly reduced and increased, respectively. In CAMP, the hazard ratios for an exacerbation after 1-year follow-up in the low-risk and high-risk groups were 0.6 (95% CI, 0.5-0.7) and 1.9 (95% CI, 1.4-2.4), respectively, with similar results at 2 years. 
Chatham protocol 11 ; the test was terminated if the FEV 1 declined by Ն 20% from the best FEV 1 after inhalation of saline solution. Allergy skin testing was performed using the ISAAC protocol. 12 Antigens tested for were dust mite ( Dermatophagoides pteronyssinus ), cockroach ( Blatella germanica and Periplaneta americana ), cat dander, dog dander, mixed grass pollen, mixed tree pollen, and Alternaria tenuis .
Validation Population
Data for the external validation sample were taken from the Childhood Asthma Management Program (CAMP), a double-blind, placebo-controlled study of the long-term effects of budesonide and nedocromil on lung growth in children. Details on the design and methods of CAMP have been published elsewhere. 13, 14 Children with asthma aged 5 to 12 years were assigned to one of three treatment arms (budesonide, nedocromil, or placebo) and followed for 4 years. The protocol for CAMP was approved by the institutional review boards of each of the participating clinical sites and by the CAMP Data Coordinating Center in Baltimore, Maryland.
Statistical Analysis
Based on recommendations from the Expert Panel Report 3 (EPR-3) from the NHLBI for the diagnosis and management of asthma, 4 we defi ned a severe exacerbation as any hospitalization or two or more ED or urgent care visits. Scheduled physician visits were not considered. This defi nition (EPR-3 outcome) was our main outcome for the exploratory phase of the present study and for the construction of the clinical score. To further assess our clinical score, we used a secondary defi nition of a severe asthma exacerbation (any hospitalization, ED or urgent care visit, or systemic steroid burst for asthma in the previous year) that was recently proposed by the ATS/European Respiratory Society (ERS) for clinical trials. 15 The database for Costa Rica was randomly split in two sets: one for the exploratory analysis (n 5 465) and one for validation of the clinical score (n 5 150). These numbers were calculated to achieve . 90% power to detect a 20% difference in the outcome. Univariate analyses were conducted to identify variables to be included in the multivariate analysis. We then used principal component analysis (PCA) to identify clusters of variables and build a clinical score to stratify subjects by risk. Finally, we evaluated the performance of this score in the Costa Rican validation set and in CAMP.
Univariate analyses were conducted using Fisher exact tests for categorical variables and two-tailed t tests for categorical and continuous variables. Stepwise logistic regression was then used; initial models included variables associated with an exacerbation at P , .20 and potential confounders. All fi nal models included age, sex, and parental education level as well as variables that were signifi cant at P , .05 or led to a Ն 10% change in risk measures.
PCA with varimax rotation was used to explore the relationships among signifi cant variables. PCA is a statistical technique that condenses the information from a large set of variables into a reduced number of factors that can explain the common variance of the sample. Factors with an eigenvalue . 1 were used to build the score. For ease of use, only questionnaire variables were included in the fi nal score, which was then evaluated in the internal validation set in Costa Rica.
To assess the performance of the clinical score in a different population, we applied it to CAMP using both our main and our secondary outcomes. The score was applied at baseline (before randomization) and evaluated by Cox survival analysis adjusted for age, sex, race, and treatment arm. We limited our analysis of CAMP to the fi rst 2 years because prediction beyond that extended past the age range of the Costa Rican children and because most exacerbations occurred in the fi rst year of the CAMP. All analyses exacerbations in childhood in Hispanics, such as Costa Ricans.
In this study, we fi rst identifi ed risk factors for asthma exacerbations in Costa Rican children. Given the paucity of clinically relevant tools to predict asthma exacerbations, we then developed and validated a predictive score for asthma exacerbations that we further validated in a cohort of North American children with asthma.
Materials and Methods

Study Population
A detailed description of the study methods is provided in the e-Appendix 1 and e- Table 1 . Children who participated in this study were index cases for a family-based study of the genetics of asthma in Costa Rica. Subject recruitment and study procedures have been described in detail elsewhere. 6, 7 The study was approved by the Institutional Review Boards of the Hospital Nacional de Niños (San José, Costa Rica) and Brigham and Women's Hospital (Boston, MA).
Questionnaires and Laboratory Testing
Parents of the study participants completed slightly modifi ed versions of the Collaborative Study on the Genetics of Asthma 8 and the ISAAC questionnaires. 9 Spirometry was conducted with a Survey Tach Spirometer (Warren E. Collins; Braintree, MA) following American Thoracic Society (ATS) recommendations. 10 On a subsequent visit, children with an FEV 1 Ն 65% predicted underwent methacholine challenge using a modified version of the Manuscript received October 10, 2009; revision accepted April 13, 2010. and validation data sets (e- Table 2 ). The baseline characteristics of the 465 children in the exploratory data set are shown in Table 1 . The age of participants ranged from 6 to 14 years. Physician-diagnosed hay fever, parental history of asthma and hay fever, and skin test reactivity (STR) to one or more allergens were all common; mean total IgE level was elevated. Of the 465 participants, 367 (80%) used short-acting b 2-agonists, 27 (6%) used xanthines, and 178 (38%)
were performed with SAS, version 9.1, statistical software (SAS Institute; Cary, NC).
Results
Costa Rican Cohort
A total of 615 children with asthma enrolled in the study had information on exacerbations. There were no significant differences between the exploratory increased odds of exacerbations. (Inclusion of both variables in the same model was not possible because of high colinearity.)
Clinical Score in the Exploratory Data Set
Factor analysis identifi ed 10 clusters of variables in the exploratory set in Costa Rica (e- Figure 1 , e- Table 3) corresponding to six categories: asthma symptoms, health-care utilization, medical history, asthma medications, laboratory tests, and airway responsiveness. A scoring questionnaire was built using these categories, excluding laboratory tests and airway responsiveness for ease of use. The resulting score with 17 total points was grouped in four categories ( Fig 1 ) . In our exploratory set, the mean 6 SD total score was 6.85 6 2.25 (range, 0-14), and the median score was 7 (interquartile range, 5-8). We classifi ed patients into three groups: low risk (score, Յ 5), intermediate or average risk (score, [6] [7] [8] , and high risk (score, Ն 9).
The multivariate analysis in the exploratory set showed that each 1-point increment in the score resulted in a 1.75-fold increment in the odds of an exacerbation (95% CI, 1.5-2.0; P , .0001). The coeffi cient of determination for this model was R 2 5 0.31, and the C statistic (equivalent to the receiver operating characteristic area under the curve [AUC]) was 0.79. Based on our main outcome, children in the low-risk group had markedly reduced odds for an asthma exacerbation, whereas those in the high-risk group had greatly increased odds for an exacerbation ( Table 3 ) . Of the 93 children in the high-risk group, 87 had an exacerbation (predictive value [PV], 93.6%), with a false-positive rate (FPR) (1-specifi city) of 4.2%. Of the 121 children in the low-risk group, 67 did not have an exacerbation (PV, 55.4%; FPR, 16.7%). Based on the EPR-3 and ATS/ERS defi nitions, 324 (69.7%) and 383 (82.4%) children had an exacerbation in the previous year, respectively. A total of 27 (5.8%) children were hospitalized in the previous year.
Predictors of Exacerbations in Costa Rica
The results of the univariate analyses of asthma exacerbations are shown in Table 1 . Variables significantly associated with asthma exacerbations were age, height, bronchiolitis or pneumonia during infancy, maternal eczema, paternal history of hay fever, asthma symptoms Ն 3 months/year, dyspnea when walking uphill, more than four scheduled physician visits for asthma in the previous year, and use of certain medications (short-acting b 2 -agonists, antiinfl ammatory medications, and one or more courses of oral steroids) in the prior year. Markers of lung function and allergy that showed signifi cant associations were baseline FEV 1 and FEV 1 /FVC ratio; change in FEV 1 /FVC ratio after use of a bronchodilator; airway responsiveness to methacholine challenge (as log-transformed dose-response slope); eosinophil count; positive IgE test for dust mite, cockroach, and Ascaris lumbricoides ; and STR to one or more allergens.
The results of the multivariate analysis of asthma exacerbations are shown in Table 2 . Children with an exacerbation were more likely to have paternal history of hay fever, four or more scheduled physician visits, a higher number of oral steroid bursts in the previous year, and asthma symptoms for Ն 3 months/year than children without an exacerbation. Additionally, total IgE level and eosinophil count were associated with ( Table 4 ) .
Validation in CAMP
The characteristics of the CAMP cohort are shown in Table 1 . The Costa Rican and CAMP cohorts were similar with regard to age, sex, lung function, and total IgE level. Severe exacerbations at 1 and 2 years of follow-up were less frequent in CAMP than in Costa Rica (main outcome, 33% vs 48%, respectively; Of interest, there was only one hospitalization for asthma among children at low risk (PV for no hospitalizations, 99.2%). Similar results were obtained for our secondary outcome ( Table 4 ) .
Clinical Score in the Validation Set
The results of the multivariate analysis were similar to those in the exploratory set: each 1-point increment in the clinical score was associated with a 1.6-fold increment in the odds of an exacerbation (95% CI, 1.3-2.0; P , .0001); the AUC was 0.75, and the odds ratio for an exacerbation in both the low-risk and high-risk groups were similar to those in the exploratory set. Of 30 children in the high-risk group, 
Discussion
To our knowledge, this study is the fi rst to examine risk factors for asthma exacerbations in a wellcharacterized cohort of Hispanic children. We constructed a checklist-type clinical score to identify Costa Rican children at low and high risk for asthma exacerbations. This score performed well in the exploratory and validation sets, indicating good reproducibility. In Costa Rica, compared with children at average risk for exacerbations, children at low risk had 0.2 times lower odds for exacerbations, and children at high risk had fi ve to eight times higher odds for exacerbations. When applied to a cohort of North American children with asthma participating in a clinical trial (CAMP), the magnitude of the effect was attenuated, but the results were consistent: Compared with children at average risk for exacerbations, children with a low score had a 40% lower risk, and children with a high score had a 90% higher risk .
The PVs allow us to predict how many of the children in a category will have the outcome. The PV of secondary outcome, 56% vs 66%, respectively). The clinical score in CAMP had similar characteristics to that in Costa Rica (mean, 6.35 6 1.9; range, 1-13; median, 6; interquartile range, 5-8).
At 1 and 2 years of follow-up, each 1-point increment in the score was associated with a ‫ف‬ 25% increased risk of exacerbations (95% CI, 1.2-1.4; P , .0001). The AUC was 0.69 at 1 year and 0.66 at 2 years. Compared with children in the average-risk group, those in the low-risk group had a 40% reduction in the risk of exacerbations at both 1 and 2 years of follow-up, and those in the high-risk group had a 90% increase in their risk at 1 and 2 years of follow-up ( Table 3 ). The PV for the high-risk group was 48% for year 1 and 68% for year 2, with an FPR of 10.5% and 8.3%, respectively. The PV for the low-risk group was 75% for year 1 and 61% for year 2, with an FPR of 26.7% and 28.9%, respectively. Similar to our fi ndings in Costa Rica, the PV of the low-risk group was higher for hospitalizations ( ‫ف‬ 94%). Similar results were found for our secondary outcome ( Table 4 ) . Figure 2 and Table 5 show the Kaplan-Meier survival curves and hazard ratios for exacerbations for each of the score categories. There was a statistically signifi cant difference among the three groups for both our main and secondary outcomes starting at history of atopy) and health-care utilization (eg, unscheduled visits and hospitalizations). Despite these differences, we were able to predict the risk of asthma exacerbations in CAMP after 1 and 2 years of follow-up. Identifi cation of risk factors for asthma morbidity (from genetics, to in utero factors, to environmental exposures [16] [17] [18] [19] [20] [21] [22] [23] [24] ) has had limited success. 19, 25 Although two computer-based models had good predictive performances for asthma morbidity (AUC, 0.70-0.78), 16, 18 they required a detailed clinical record integrated with medication refi ll information. We obtained results similar to those of more complex models (training set AUC, 0.76; validation phases AUC, 0.65-0.73) using variables attainable in a physician's offi ce. The performance of our score compares well with those used for other diseases. [26] [27] [28] For example, acute physiology and chronic health evaluation scores have an AUC of 0.66 to 0.79 when assessing prognosis in cirrhosis and severe sepsis. 26, 27 Factor analysis and PCA inspect multiple variables and look at interrelations and clustering to identify the underlying structure of a large set of variables. 29, 30 Rather than evaluating variables in relationship to an outcome (as in regression analysis), factor analysis the score's high-risk group was 97% in Costa Rica and 69% to 78% in CAMP, meaning that between 70% and 90% of children classifi ed as high risk will indeed have a severe exacerbation. The usefulness of having a low-risk group was less clear cut, with the PV being 36% to 40% in Costa Rica and 51% to 61% in CAMP. The differences in PVs are expected because of the lower prevalence of exacerbations in CAMP. Importantly, the low-risk group had a very high PV for no hospitalizations in both cohorts (94%-99%). To make our results comparable for future studies, we included a second defi nition of an asthma exacerbation based on ATS/ERS defi nitions. This outcome was more prevalent in our cohorts (leading to variation in the PVs), but the overall results and risk ratios were similar and remained signifi cant.
Several differences existed between the study cohorts. Costa Rica was a cross-sectional study, whereas CAMP was a prospective clinical trial. Participation in a clinical trial has been shown to increase adherence and improve outcomes. Whereas CAMP included children with mild to moderate persistent asthma, the Costa Rican cohort had a broader range of severity. Differences also existed between the cohorts with regard to medical history (eg, family There are several limitations to our study. First, the predictive score was built in a cross-sectional study. Without a prospective timeline, it is diffi cult to assess whether the risk factors really antedated the outcomes or whether they were related, and this can lead to signifi cant diffi culties in the interpretation of the results. However, we were able to evaluate outcomes over 2 years of follow-up by applying the score to CAMP, where the score's predictive utility remained signifi cant over time. Second, there was an appreciable reduction in risk ratios and PVs in CAMP compared with Costa Rica, which likely refl ects the different characteristics described previously. Costa Rica had a higher prevalence of exacerbations and a broader spectrum of disease severity, and importantly, the score was originally designed using this cohort. Third, the PCA technique shows correlations and PCA describe how variables are related to one another. Each resulting factor comprises several variables that may refl ect a unique disease aspect. By using different factors, we aimed to cover multiple disease aspects. Although a few studies have used factor analysis and PCA to identify components of asthma morbidity and care, [31] [32] [33] none have evaluated such components in relation to clinical outcomes. 29 To our knowledge, this study is the first to build a clinical score based on factor analysis and PCA and to evaluate its performance and predictive utility both in a validation subset and in an independent cohort. Although exclusion of laboratory and pulmonary function data eliminated some of the identified clusters, we were interested in developing a predictive score for use in primary-care settings in different countries. Dr Soto-Quirós: contributed to the data collection and the drafting of the manuscript and review of its fi nal version. Dr Avila: contributed to the data collection and the drafting of the manuscript and review of its fi nal version. Dr Raby: contributed to the data analysis and the drafting of the manuscript and review of its fi nal version. Dr Brehm: contributed to the data analysis and the drafting of the manuscript and review of its fi nal version. Ms Sylvia: contributed to the data collection and the drafting of the manuscript and review of its fi nal version. Dr Weiss: contributed to obtaining funding, the study design, data analysis, and the drafting of the manuscript and review of its fi nal version. Dr Celedón: contributed to obtaining funding, the study design, data collection, data analysis, and the drafting of the manuscript and review of its fi nal version. among the variables introduced, but it does not indicate whether using more variables would improve the results. Finally, the goodness of fi t for Costa Rica and the fi rst year of CAMP were high, indicating a very good calibration of the score, but it was lower in year 2 (e- Table 4 ), which may imply that the instrument is not as accurate that far out.
Developing an effective predictive score for clinical practice is potentially important for identifying patients at high or low risk for asthma exacerbations and would allow providers to improve management, better allocate treatment, and make referrals when necessary. The practical usefulness of such a score, on the other hand, depends on its ease of use and interpretability. Including more variables and components may yield a more accurate tool, but the trade-off would be to produce an instrument that is too lengthy and, thus, too cumbersome for clinical practice.
In summary, we present a clinical score that is effective at identifying groups of children with asthma at high risk for exacerbations. The score is designed as a checklist questionnaire and excludes laboratory data in order to be easily used in primary-care settings, particularly in areas with few resources or where access to subspecialty care is diffi cult. Ideally, this tool should be prospectively assessed in a cohort in this type of population. If validated, a next step would be to evaluate whether it is useful in guiding or adjusting therapy. To ensure generalizability, we recommend using the ATS/ERS defi nitions for mild, moderate, and severe asthma exacerbations in future prospective studies assessing this score.
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